| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.29 | 2e-09 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.21 | 2e-05 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.1 | 0.03 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.08 | 0.09 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.082 | 0.1 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.069 | 0.2 |